Yes, GLP-1 is a peptide. Glucagon-like peptide-1 is a hormone 30 amino acids long, written GLP-1(7-36) amide, cut out of a larger precursor protein called proglucagon. Its chain is held together by peptide bonds, which is the definition of a peptide. Semaglutide, liraglutide and the other GLP-1 analogs are modified copies of that chain.
- GLP-1 is a peptide: the active hormone GLP-1(7-36) amide is 30 amino acids long with the sequence HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR and an amidated C-terminus.
- GLP-1 is cut from proglucagon, a 180-residue precursor; UniProt P01275 places GLP-1(7-36) at proglucagon positions 98 to 127.
- DPP-4 removes the first two residues of GLP-1, producing GLP-1(9-36) amide, with an in-vitro half-life of 20.4 minutes in human plasma reported in 1995.
- Liraglutide is 97% homologous to GLP-1 with a C16 fatty acid on lysine 26; semaglutide is 94% homologous with a C18 fatty diacid on lysine 26 and a change at position 8.
- Exenatide is a 39-residue peptide amide first identified in the lizard Heloderma suspectum, with partial sequence overlap to human GLP-1.
- Dulaglutide is a fusion protein of about 63 kDa made of two GLP-1 analog chains each linked to a modified IgG4 Fc region.
What this guide covers
The question "is GLP-1 a peptide" comes up because the letters look like a product code rather than a molecule. GLP stands for glucagon-like peptide, so the answer is in the name, but the name alone does not say what the molecule is or how the drugs built from it differ.
This page gives the sequence of the natural hormone, explains which larger protein it is cut from, shows the one enzyme step that limits how long it lasts, and lays out how four approved analogs changed the chain. It is a chemistry reference for a laboratory reader. It does not describe what any of these molecules does in a person, and it does not cover handling of a vial.
- Proglucagon: 180 residues made in gut L-cells
- GLP-1(1-37) cut out at positions 92 to 128
- Six residues trimmed: GLP-1(7-37), 31 residues
- Terminal glycine converted: GLP-1(7-36) amide, 30 residues
- DPP-4 removes His-Ala: GLP-1(9-36) amide within minutes
- Analogs block that cut and add a fatty acid
Is GLP-1 a peptide?
GLP-1 is a peptide: a short chain of amino acids joined end to end by peptide bonds. The IUPAC-IUB nomenclature defines a peptide as any compound formed by amide bonds between the carboxyl group of one amino acid and the amino group of the next, with no upper size limit written into the definition. GLP-1 meets it with room to spare.
The active form in the body is GLP-1(7-36) amide, which is 30 amino acids long. In one-letter code the sequence, read from the UniProt record for human proglucagon (P01275), is HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR, with the final arginine carrying an amide group instead of a free carboxylic acid. A second form, GLP-1(7-37), adds one glycine at the end and is 31 residues long. Both occur naturally. A review in Physiological Reviews (2007) describes GLP-1 as a 30-amino acid peptide hormone, which is the amidated form.
Thirty residues puts GLP-1 well inside the range most chemists call a peptide rather than a protein. Our guide on polypeptide chains covers where that line is usually drawn and why it is a convention rather than a rule, and the peptide bond explains the link itself.
Where does GLP-1 come from? Proglucagon and its pieces
GLP-1 is cut from a larger precursor protein called proglucagon, which is 180 amino acids long. UniProt's record for human proglucagon (P01275) lists the pieces that different cells carve out of it. The first 20 residues are a signal sequence removed on the way out of the cell. The rest holds several hormones laid end to end.
The numbering in the name GLP-1(7-36) refers to a 37-residue stretch, GLP-1(1-37), that sits at positions 92 to 128 of proglucagon. The first six residues of that stretch are removed, leaving GLP-1(7-37) at proglucagon positions 98 to 128, or GLP-1(7-36) amide at positions 98 to 127 once the terminal glycine is converted into the amide group. So "7" and "36" count from the start of the 37-residue stretch, not from the start of proglucagon and not from the start of the final hormone. That is why the active peptide's first residue, histidine, is called His7 in the literature even though it is the first residue in the chain.
| Peptide | Proglucagon positions | Length |
|---|---|---|
| Signal sequence (removed) | 1 to 20 | 20 |
| Glicentin | 21 to 89 | 69 |
| Glucagon | 53 to 81 | 29 |
| Oxyntomodulin | 53 to 89 | 37 |
| GLP-1(1-37) | 92 to 128 | 37 |
| GLP-1(7-37) | 98 to 128 | 31 |
| GLP-1(7-36) amide | 98 to 127 | 30 |
| GLP-2 | 146 to 178 | 33 |
Glucagon and GLP-1 sit in the same precursor and share a family resemblance in sequence, which is where the "glucagon-like" in the name comes from. Oxyntomodulin is glucagon plus eight more residues. Some newer research peptides are built on oxyntomodulin or glucagon rather than on GLP-1, and the table is the quickest way to see why those are relatives rather than copies.
Why does native GLP-1 last only minutes? The DPP-4 cut
Native GLP-1 is broken down quickly by an enzyme called dipeptidyl peptidase-4, usually written DPP-4 or DPP-IV. The enzyme removes the first two amino acids, histidine and alanine, from the start of the chain. What is left is GLP-1(9-36) amide, a 28-residue fragment.
A 1995 study in the Journal of Clinical Endocrinology and Metabolism measured this directly. Human plasma incubated with GLP-1(7-36) amide at 37 degrees Celsius converted it into an N-terminally truncated peptide with a half-life of 20.4 minutes in the test tube, and DPP-IV inhibitors or cooling to 4 degrees stopped the conversion. Mass spectrometry and sequencing confirmed the product as GLP-1(9-36) amide, and the authors saw no breakdown at the other end of the chain. A companion study the same year in Diabetes found the same fragment forming rapidly in people.
The chemistry of the cut is simple. DPP-4 prefers a chain whose second residue is alanine or proline. GLP-1 has alanine at position 8 (the second residue of the active hormone). Swap that alanine for something the enzyme cannot grip, and the cut slows or stops. Several analogs make exactly that change: semaglutide carries a substitution at position 8, dulaglutide swaps it for glycine, and exenatide has glycine there by nature. Liraglutide keeps the alanine and relies on its fatty acid instead, so reading position 8 is the first useful step with any analog's structure description.
For a laboratory, this also explains why GLP-1(7-36) amide and GLP-1(9-36) amide must be told apart on a certificate. They differ by two residues, His-Ala, which is a mass difference of about 208 Da. A mass spectrum resolves that; an HPLC purity percentage does not say which one the peak is.
How do GLP-1 analogs change the native peptide?
A GLP-1 analog is a peptide whose chain is based on native GLP-1 with deliberate changes, and the FDA labels for the approved analogs describe those changes in their Description sections. Three strategies recur: block the DPP-4 cut, attach a fatty acid so the molecule binds albumin in blood, or fuse the peptide to a much larger protein.
| Molecule | Relation to native GLP-1 | Main changes | Formula and mass |
|---|---|---|---|
| Native GLP-1(7-36) amide | The hormone | None; 30 residues, amidated | About 3,298 Da (30-residue amide) |
| Liraglutide | 97% homologous | Arginine for lysine at position 34; a C16 fatty acid (palmitic acid) attached through a glutamic acid spacer to lysine 26 | C172H265N43O51; 3,751.2 Da |
| Semaglutide | 94% homologous | Position 8 changed to resist DPP-4; lysine 26 carries a hydrophilic spacer and a C18 fatty diacid; a minor change at position 34 so only one diacid attaches | C187H291N45O59; 4,113.58 g/mol |
| Exenatide | Partial sequence overlap | A 39-residue peptide amide first identified in the lizard Heloderma suspectum, not derived from the human sequence | C184H282N50O60S; 4,186.6 Da |
| Dulaglutide | GLP-1 portion 90% homologous to GLP-1(7-37) | Two GLP-1 analog chains each linked to a modified human IgG4 Fc region; made in Chinese hamster ovary cells | About 63 kDa |
The native mass in the first row is a calculated value for the 30-residue amidated sequence, given for scale. The other rows quote the labels.
Liraglutide and semaglutide are the closest copies. Each keeps almost the whole human sequence and adds a fatty acid at lysine 26, which is why both are still peptides in every sense and simply carry a lipid tail. Exenatide takes a different route: it is the synthetic form of a lizard peptide whose sequence happens to overlap GLP-1, and its own chain lacks the alanine that DPP-4 needs. Dulaglutide stops being a small peptide at all. Two GLP-1-like chains are fused to an antibody fragment, and the result is a glycosylated protein about twenty times the mass of the hormone.
Tirzepatide, retatrutide and the other multi-receptor research peptides are often lumped in with GLP-1 analogs, but their backbones come from a different gut hormone, GIP. Our guide on whether tirzepatide is a peptide covers that structure, and the GLP-3 nickname for retatrutide explains why "GLP-3" is not a real hormone.
Why the classification matters on a certificate
Calling GLP-1 a peptide is more than a vocabulary point. It tells a laboratory which tests confirm identity and which cannot.
- A peptide has a sequence, so a mass spectrometer can compare the measured mass against the calculated mass of that sequence. For semaglutide that reference is 4,113.58 g/mol from the label and 4,114 average mass from PubChem (CID 56843331). For a 30-residue native hormone it is about 3,298 Da.
- A peptide with a fatty acid attached has a mass that includes the fatty acid. A certificate for liraglutide or semaglutide that reports the bare backbone mass is describing a different molecule.
- A fusion protein like dulaglutide is glycosylated, so it has no single exact mass. Its certificate looks nothing like a small peptide's and should not be read as one.
- Fragments matter. GLP-1(7-36) amide and GLP-1(9-36) amide differ by two residues, and a listing for "GLP-1" that does not say which form it means has not identified the compound.
Our guide on HPLC purity versus identity explains why a purity percentage alone cannot answer any of these questions, and the semaglutide identity guide walks through a certificate for the most common analog. For the compound itself, see our semaglutide product page; each lot's certificate is posted at /coa/.
Reading a GLP-1 listing: step by step
- Find out which molecule is meant. "GLP-1" on a vial could be the native hormone, a fragment, or an analog sold under the class name. A sequence or a formula settles it. A name alone does not.
- If it is the native hormone, check whether the listing says (7-36) amide or (7-37). They differ by one glycine and by the amide group, about 58 Da apart.
- If it is an analog, look for the fatty acid or spacer in the description and make sure the quoted mass includes it.
- Compare the certificate's deconvoluted mass against the right reference value from the table above or from PubChem.
- Match the lot number on the certificate to the lot on the vial, then read the HPLC purity figure as a second, separate piece of information.
For the regulatory picture, our guide to FDA-approved peptide drugs lists which GLP-1 analogs are in approved medicines, and compounded semaglutide covers what happened to compounding after the shortage ended.
Bottom line
GLP-1 is a peptide: 30 amino acids, HAEGTFTSDVSSYLEGQAAKEFIAWLVKGR with an amide at the end, cut from positions 98 to 127 of the 180-residue precursor proglucagon. DPP-4 removes its first two residues within minutes, and the approved analogs exist mostly to stop that cut and to stay in blood longer, by swapping position 8, attaching a fatty acid at lysine 26, or fusing the chain to an antibody fragment. Which of those a vial holds is a question a mass spectrum answers and a label does not.
FOR LABORATORY AND IN-VITRO RESEARCH USE ONLY. NOT FOR HUMAN OR ANIMAL CONSUMPTION. NOT FOR PERSONAL, MEDICAL, DIAGNOSTIC, THERAPEUTIC, OR RECREATIONAL USE.
Common questions
Is GLP-1 a peptide or a protein?
What is the GLP-1 amino acid sequence?
Is semaglutide the same as GLP-1?
What does DPP-4 do to GLP-1?
Is tirzepatide a GLP-1 peptide?
Published certificates for Semaglutide
Every figure below is read from a report the laboratory issued for that lot; each page carries the PDF and the lab's own verification link.
More science guides
Sources
- UniProt P01275, Pro-glucagon (human). 180-residue precursor sequence and the peptide features: glicentin 21-89, glucagon 53-81, oxyntomodulin 53-89, GLP-1 92-128, GLP-1(7-37) 98-128, GLP-1(7-36) 98-127 with C-terminal amidation, GLP-2 146-178.
- Holst JJ. The physiology of glucagon-like peptide 1. Physiological Reviews 87(4):1409-1439 (2007) doi:10.1152/physrev.00034.2006. Describes GLP-1 as a 30-amino acid peptide hormone produced by differential processing of proglucagon and rapidly inactivated by dipeptidyl peptidase IV.
- Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. Journal of Clinical Endocrinology and Metabolism 80(3):952-957 (1995) doi:10.1210/jcem.80.3.7883856. Human plasma converts GLP-1(7-36) amide to GLP-1(9-36) amide with a half-life of 20.4 minutes at 37 C; DPP-IV inhibitors prevent it; product confirmed by mass spectrometry and sequencing.
- Ozempic (semaglutide) prescribing information, DailyMed, sections 11 and 12.1. 94% sequence homology to human GLP-1; position 8 modified against DPP-4; lysine 26 with a hydrophilic spacer and C18 fatty di-acid; minor change at position 34; C187H291N45O59, 4113.58 g/mol.
- Victoza (liraglutide) prescribing information, DailyMed, section 11. 97% homologous to native human GLP-1 by substituting arginine for lysine at position 34; C-16 fatty acid (palmitic acid) with a glutamic acid spacer on lysine 26; C172H265N43O51, 3751.2 daltons.
- Byetta (exenatide) prescribing information, DailyMed, sections 11 and 12.1. A 39-amino acid peptide amide originally identified in the lizard Heloderma suspectum; C184H282N50O60S, 4186.6 daltons; sequence partially overlaps human GLP-1.
- Trulicity (dulaglutide) prescribing information, DailyMed, section 11. Fusion protein of two identical disulfide-linked chains, each an N-terminal GLP-1 analog sequence 90% homologous to native human GLP-1(7-37) linked to a modified human IgG4 Fc region; about 63 kilodaltons; made in CHO cells.
- IUPAC-IUB JCBN, Nomenclature and Symbolism for Amino Acids and Peptides, 3AA-11 Definitions of Peptides. Defines a peptide as any compound produced by amide formation between a carboxyl group of one amino acid and an amino group of another.

